WO1997029770A1 - Vaccin contre la sarcocystose - Google Patents
Vaccin contre la sarcocystose Download PDFInfo
- Publication number
- WO1997029770A1 WO1997029770A1 PCT/AU1996/000419 AU9600419W WO9729770A1 WO 1997029770 A1 WO1997029770 A1 WO 1997029770A1 AU 9600419 W AU9600419 W AU 9600419W WO 9729770 A1 WO9729770 A1 WO 9729770A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bradozooids
- vaccine
- toxin
- protozoa
- sarcocystis
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 34
- 241000224003 Sarcocystis Species 0.000 title claims abstract description 25
- 208000015181 infectious disease Diseases 0.000 claims abstract description 10
- 238000002649 immunization Methods 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000003053 toxin Substances 0.000 claims description 35
- 231100000765 toxin Toxicity 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 13
- 244000309464 bull Species 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 150000003868 ammonium compounds Chemical group 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 230000006862 enzymatic digestion Effects 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 108700012359 toxins Proteins 0.000 description 28
- 244000045947 parasite Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000006775 Sarcocystosis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
Definitions
- the present invention relates to a vaccine for immunisation against infections caused by the toxin of the Sarcocystis protozoa in the hosts of the parasite, as well as by toxins which are closely related in chemical structure and physiological effect to such toxin.
- the present invention also relates to a method for producing the vaccine.
- the present invention is based on research developed by us on infections due to toxicogenic Sarcocystis, which are able to provide the toxin (Sarcocystine). It has been found that the toxin has the capacity to alter the normal function of blood microcirculation of B and T lymphocytes and the coagulation factors of blood, producing a chronic passive congestion with extravasation of liquids and solids in the form of oedema and or haemorrhage in the different organs that are irrigated dirough blood microcirculation.
- the central nervous system because the blood never comes in contact with the myelin, thanks to the system of the hematoencephalic barrier (HB), it is clear that if a patient presents with Sarcocystine, then oedemas and/or haemorrhages will be produced in the CNS. This leads us to conclude that the toxin is capable of breaking through the HB, and of increasing the blood lymphocyte count by its mitogenic capacity. In addition the parasite toxin has the capacity to increase the concentrations of the tumoral necrosing factor. When the toxin is administered in experimental infections it has been possible to reproduce demyelinating lesions, even developing Central Nervous System dysfunctions, hemiplegia, paraplegia and quadriplegia.
- the vaccines may also include other agents conventional in the art having regard to the mode of administration, for example, those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents, disintegrating agents, coating agents, preservatives, lubricants and/or time delay agents.
- those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents, disintegrating agents, coating agents, preservatives, lubricants and/or time delay agents.
- at least one pharmaceutically acceptable sugar is present.
- the parasite bradozooids are extracted from the muscle tissue by artificial digestion by pancreatic trypsin and they are then purified by density gradients with Percol
- Percol is colloidal polyvinyl pyrrolidone "PVP" coated silica particles which are known in the art for the purpose of cell separation.
- a formulation is preferably made as follows: -
- the present invention provides a vaccine which is effective in humans against the Sarcocystine toxin and toxins of a like kind. Experiments with male New Zealand rabbits have already established the viability of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne un vaccin pour immuniser contre les infections produites par les protozoaires du genre Sarcocystis, contenant des bradozooïdes lyophilisés et inactivés de protozoaires du genre Sarcocystis, ainsi qu'un vecteur acceptable sur le plan pharmaceutique. L'invention concerne également un procédé pour produire le vaccin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU62938/96A AU6293896A (en) | 1996-02-16 | 1996-07-05 | Sarcocystis vaccine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9603303A GB2310135A (en) | 1996-02-16 | 1996-02-16 | Sarcocystis vaccine:lyophilized bradyzoites |
| GB9603303.0 | 1996-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997029770A1 true WO1997029770A1 (fr) | 1997-08-21 |
Family
ID=10788893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU1996/000419 WO1997029770A1 (fr) | 1996-02-16 | 1996-07-05 | Vaccin contre la sarcocystose |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU6293896A (fr) |
| GB (1) | GB2310135A (fr) |
| WO (1) | WO1997029770A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7169398B2 (en) * | 2000-04-25 | 2007-01-30 | Wyeth | Equine protozoal myeloencephalitis vaccine |
-
1996
- 1996-02-16 GB GB9603303A patent/GB2310135A/en not_active Withdrawn
- 1996-07-05 WO PCT/AU1996/000419 patent/WO1997029770A1/fr active Application Filing
- 1996-07-05 AU AU62938/96A patent/AU6293896A/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| AMERICAN JOURNAL OF VETERINARY RESEARCH, Volume 51, No. 7, issued July 1990, D.E. GRANSTROM et al., "Immunodominant Proteins of S. Cruzi Bradyzoites Isolated from Cahle Affected or Non Affected with Cosinophilic Myositis", pages 1151-1155. * |
| THE JOURNAL OF PARASITOLOGY, Volume 77, No. 2, issued April 1991, A.M. TENTER et al., "Effect of Tryptic or Peptic Digestion or Mechanical Isolation on the Extraction of Proteins, Antigens and Ribonucleic Acids From S. Muris Bradyzoites", pages 194-199. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7169398B2 (en) * | 2000-04-25 | 2007-01-30 | Wyeth | Equine protozoal myeloencephalitis vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9603303D0 (en) | 1996-04-17 |
| AU6293896A (en) | 1997-09-02 |
| GB2310135A (en) | 1997-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabin | The filtrable microörganisms of the pleuropneumonia group | |
| JPH08231425A (ja) | トリの抗体を用いた哺乳動物の受動免疫化 | |
| JPH09512708A (ja) | グルカンの酵素処理 | |
| CN1037276A (zh) | 具有抗体活性和广谱作用的产品，由它们组成的或含有它们的药物，应用它们治疗与细菌或毒素有关的疾病、应用它们杀灭原虫 | |
| US4207414A (en) | Polysaccharide antigens | |
| EP0041897B1 (fr) | Antigène de polysaccharide de streptocoque et vaccins | |
| US20020044942A1 (en) | Transfer factor composition and process for producing same | |
| CN101113176A (zh) | 鸡传染性法氏囊精制蛋黄冻干抗体的制备方法 | |
| CN118048275A (zh) | 一株枯草芽孢杆菌及其在提高动物免疫力中的应用 | |
| KR880003632A (ko) | 계란으로부터의 특이적항체함유재료 및 그 제조방법과 용도 | |
| JPS6121A (ja) | ワクチンおよびその製造法 | |
| US20060182748A1 (en) | Method of creating antivenom using Emus | |
| CN1206243C (zh) | 猪传染性胃肠炎病毒卵黄抗体和抗原及其制备 | |
| US4285930A (en) | Antigens comprising immunostimulant adjuvants and their use in immunotherapy | |
| JPH0789872A (ja) | 腸原生動物のワクチン類 | |
| JPH11512746A (ja) | 乳漿中の免疫グロブリンの単離方法 | |
| JP2000210050A (ja) | 免疫調節活性分解物およびその製造方法並びにそれを用いた食品 | |
| WO1997029770A1 (fr) | Vaccin contre la sarcocystose | |
| US4902673A (en) | Enhancing growth of bifidobacteria using soybean extract | |
| RU2076734C1 (ru) | Способ получения пероральной химической вакцины | |
| Valsamidis et al. | Immune response of European sea bass (Dicentrarchus labrax L.) against combination of antigens from three different pathogens | |
| RU2077340C1 (ru) | Способ получения специфической сыворотки для лечения, диагностики и профилактики вирусной геморрагической болезни кроликов и набор для диагностики болезни | |
| JP4150631B2 (ja) | 魚類冷水病ワクチン | |
| JPH1192389A (ja) | 免疫賦活剤 | |
| RU2101020C1 (ru) | Препарат, обладающий иммуностимулирующим действием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97528817 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |